US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

NEUROGENE INC

27.21

+0.71002.68%

Volume:220.28K

Turnover:6.06M

Market Cap:544.51M

PE:-5.39

High:29.63

Open:28.90

Low:26.50

Close:26.50

52wk High:43.66

52wk Low:15.93

Shares:20.01M

Float Shares:11.34M

Volume Ratio:1.42

T/O Rate:1.94%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-5.0440

EPS(LYR):-4.2400

ROE:-45.32%

ROA:-27.97%

PB:2.51

PE(LYR):-6.42

Loading ...

Overview Company News Filings

Neurogene posts corporate deck highlighting NGN-401 gene therapy program for Rett syndrome

Neurogene Q1 net loss widens on higher R&D costs

Neurogene Q1 FY26 net loss widens to USD 30.9 million

BRIEF-Neurogene Q1 Operating Expenses USD 33.349 Million

Press Release: Neurogene Reports First Quarter 2026 Financial Results and Highlights Recent Updates

Neurogene says NGN-401 Rett trial shows milestone gains up to 24 months

Neurogene President, CFO Christine Mikail Cvijic sells USD 300,821 common shares

BRIEF-Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Neurogene grants 122,565 inducement stock options to two new employees

Neurogene Inc expected to post a loss of $1.30 a share - Earnings Preview

Guggenheim Initiates Neurogene at Buy With $69 Price Target

MT Newswires Live

Neurogene highlights NGN-401 Phase 1/2 Rett syndrome data ahead of ASGCT poster

BRIEF-Neurogene Appoints Christy Shafer As Chief Commercial Officer And Christine Mikail, J.D., To Board Of Directors

Neurogene names Christy Shafer chief commercial officer

Neurogene Appoints Christy Shafer as Chief Commercial Officer and Christine Mikail, J.d., to Board of Directors

THOMSON REUTERS

Companies Like Neurogene (NASDAQ:NGNE) Are In A Position To Invest In Growth

Simply Wall St.

Neurogene announces annual shareholder meeting

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/NGNE/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NGNE","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NGNE\",,,,,undefined,":{"symbol":"NGNE","market":"US","secType":"STK","nameCN":"NEUROGENE INC","latestPrice":27.21,"timestamp":1791565934177,"preClose":26.5,"halted":0,"volume":220281,"delay":0,"changeRate":0.02679245283018871,"floatShares":11340900,"shares":20011400,"eps":-5.044019,"marketStatus":"Trading","change":0.71,"latestTime":"10-09 13:12:18 EDT","open":28.9,"high":29.63,"low":26.5,"amount":6063836.993535,"amplitude":0.118113,"askPrice":27.37,"askSize":22,"bidPrice":26.97,"bidSize":34,"shortable":3,"etf":0,"ttmEps":-5.044019,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1791576000000},"marketStatusCode":2,"adr":0,"listingDate":1394168400000,"exchange":"NASDAQ","adjPreClose":26.5,"preHourTrading":{"tag":"盘前","latestPrice":28.7,"preClose":26.5,"latestTime":"09:24 EDT","volume":7121,"amount":204032.415894,"timestamp":1791552298328,"change":2.2,"changeRate":0.083019,"amplitude":0.117358},"postHourTrading":{"tag":"盘后","latestPrice":26.85,"preClose":26.5,"latestTime":"19:52 EDT","volume":4270,"amount":113786.02,"timestamp":1791503551350,"change":0.35,"changeRate":0.013208,"amplitude":0.018868},"volumeRatio":1.417791,"impliedVol":0.7194,"impliedVolPercentile":0.2869},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NGNE\",,,,,undefined,":{"symbol":"NGNE","floatShares":11340900,"roa":"-27.97%","roe":"-45.32%","lyrEps":-4.24,"volumeRatio":1.417791,"shares":20011400,"dividePrice":0,"high":29.63,"amplitude":0.118113,"preClose":26.5,"low":26.5,"week52Low":15.93,"pbRate":"2.51","week52High":43.66,"institutionHeld":0,"latestPrice":27.21,"committee":0.214286,"eps":-5.044019,"divideRate":0,"volume":220281,"delay":0,"ttmEps":-5.044019,"open":28.9,"prevYearClose":20.6,"prevWeekClose":25.65,"prevMonthClose":27.82,"prevQuarterClose":27.82,"fiveDayClose":25.65,"twentyDayClose":35.48,"sixtyDayClose":36.5},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NGNE\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-11","symbol":"NGNE","fiscalQuarterEnding":"2026/06","expectedEps":-1.4,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1786420800000,"reportTimeType":"pre","actualEps":-1.53},{"market":"US","date":"2026-05-12","symbol":"NGNE","fiscalQuarterEnding":"2026/03","expectedEps":-1.35,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1778558400000,"reportTimeType":"post","actualEps":-1.39},{"market":"US","date":"2026-03-24","symbol":"NGNE","fiscalQuarterEnding":"2025/12","expectedEps":-1.2,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1774324800000,"reportTimeType":"pre","actualEps":-1.12},{"market":"US","date":"2025-11-13","symbol":"NGNE","fiscalQuarterEnding":"2025/09","expectedEps":-1.26,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1763010000000,"reportTimeType":"post","actualEps":-0.99},{"market":"US","date":"2025-08-11","symbol":"NGNE","fiscalQuarterEnding":"2025/06","expectedEps":-1.15,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1754884800000,"reportTimeType":"post","actualEps":-1.05}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NGNE\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NGNE\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.4,"buy":0.6,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6,"analysts":10,"updateTime":1777435200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/NGNE\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"NGNE","date":"2026-10-08","current":-5.394508,"percent":0.567208,"low":-19.523035,"twenty":-9.739983,"median":-5.001181,"eighty":-3.495349,"high":-1.458307,"avg":-6.439381,"sd":3.611194,"marketCap":517694452},"quantilePoints":[{"date":"2023-12-29","current":-4.323556,"twenty":-4.185645,"median":-3.978778,"eighty":-3.916869,"marketCap":220311097},{"date":"2024-01-05","current":-5.423319,"twenty":-5.000527,"median":-4.624292,"eighty":-3.978778,"marketCap":276350648},{"date":"2024-01-12","current":-8.005373,"twenty":-7.157271,"median":-5.423319,"eighty":-4.323556,"marketCap":407921769},{"date":"2024-01-19","current":-7.59768,"twenty":-7.599292,"median":-7.086806,"eighty":-4.804734,"marketCap":387147382},{"date":"2024-01-26","current":-8.053188,"twenty":-7.611677,"median":-7.561189,"eighty":-4.985427,"marketCap":410358272},{"date":"2024-02-02","current":-7.741127,"twenty":-7.937424,"median":-7.577547,"eighty":-5.338761,"marketCap":394456888},{"date":"2024-02-09","current":-7.497015,"twenty":-7.980207,"median":-7.59013,"eighty":-6.388695,"marketCap":382017903},{"date":"2024-02-16","current":-7.549864,"twenty":-7.937424,"median":-7.577547,"eighty":-6.995453,"marketCap":384710880},{"date":"2024-02-23","current":-7.622846,"twenty":-7.894138,"median":-7.57503,"eighty":-7.129085,"marketCap":388429751},{"date":"2024-03-01","current":-7.819143,"twenty":-7.894138,"median":-7.588872,"eighty":-7.262969,"marketCap":398432234},{"date":"2024-03-08","current":-9.734292,"twenty":-8.024499,"median":-7.59768,"eighty":-7.381754,"marketCap":496020561},{"date":"2024-03-15","current":-8.697444,"twenty":-8.083388,"median":-7.629138,"eighty":-7.463796,"marketCap":443186933},{"date":"2024-03-22","current":-17.419498,"twenty":-9.10262,"median":-7.660596,"eighty":-7.498525,"marketCap":632623921},{"date":"2024-03-28","current":-17.433655,"twenty":-9.373408,"median":-7.741127,"eighty":-7.499532,"marketCap":633138041},{"date":"2024-04-05","current":-15.090764,"twenty":-9.721205,"median":-7.845567,"eighty":-7.510605,"marketCap":548051280},{"date":"2024-04-12","current":-13.565408,"twenty":-14.180505,"median":-7.97769,"eighty":-7.536275,"marketCap":492654915},{"date":"2024-04-19","current":-11.176509,"twenty":-13.912948,"median":-8.029281,"eighty":-7.549864,"marketCap":405897266},{"date":"2024-04-26","current":-10.571321,"twenty":-13.650346,"median":-8.053188,"eighty":-7.549864,"marketCap":383918661},{"date":"2024-05-03","current":-12.537284,"twenty":-13.442874,"median":-8.146303,"eighty":-7.558924,"marketCap":455316556},{"date":"2024-05-10","current":-11.764996,"twenty":-13.2542,"median":-9.074937,"eighty":-7.57352,"marketCap":427269365},{"date":"2024-05-17","current":-10.587696,"twenty":-13.13876,"median":-9.272492,"eighty":-7.576037,"marketCap":433830864},{"date":"2024-05-24","current":-9.887502,"twenty":-12.800854,"median":-9.44488,"eighty":-7.581574,"marketCap":405140389},{"date":"2024-05-31","current":-10.685033,"twenty":-12.52136,"median":-9.620612,"eighty":-7.588117,"marketCap":437819226},{"date":"2024-06-07","current":-11.771752,"twenty":-12.409114,"median":-9.810897,"eighty":-7.59013,"marketCap":482347539},{"date":"2024-06-14","current":-13.301826,"twenty":-12.457666,"median":-9.93146,"eighty":-7.59013,"marketCap":545042335},{"date":"2024-06-21","current":-9.842528,"twenty":-12.564112,"median":-9.93146,"eighty":-7.59617,"marketCap":403297579},{"date":"2024-06-28","current":-11.030474,"twenty":-12.52136,"median":-10.019377,"eighty":-7.599292,"marketCap":451973662},{"date":"2024-07-05","current":-11.397945,"twenty":-12.537284,"median":-10.188931,"eighty":-7.605739,"marketCap":467030798},{"date":"2024-07-12","current":-13.232134,"twenty":-12.537284,"median":-10.458961,"eighty":-7.622846,"marketCap":542186671},{"date":"2024-07-15","current":-13.48873,"twenty":-12.644595,"median":-10.463671,"eighty":-7.625363,"marketCap":552700705},{"date":"2024-08-02","current":-12.832984,"twenty":-12.76836,"median":-10.468381,"eighty":-7.627879,"marketCap":525831507},{"date":"2024-08-09","current":-11.578513,"twenty":-12.617767,"median":-10.579508,"eighty":-7.644992,"marketCap":474429562},{"date":"2024-08-16","current":-9.721942,"twenty":-12.533918,"median":-10.468381,"eighty":-7.659841,"marketCap":462832495},{"date":"2024-08-23","current":-9.22793,"twenty":-12.500388,"median":-10.20777,"eighty":-7.686769,"marketCap":439314055},{"date":"2024-08-30","current":-9.934831,"twenty":-12.3607,"median":-10.082175,"eighty":-7.732068,"marketCap":472967513},{"date":"2024-09-06","current":-9.383503,"twenty":-12.215183,"median":-10.030358,"eighty":-7.751697,"marketCap":446720414},{"date":"2024-09-13","current":-11.015654,"twenty":-12.198503,"median":-10.056266,"eighty":-7.799009,"marketCap":524422220},{"date":"2024-09-20","current":-11.343175,"twenty":-12.111032,"median":-10.20463,"eighty":-7.829713,"marketCap":540014556},{"date":"2024-09-27","current":-10.69359,"twenty":-12.018852,"median":-10.282823,"eighty":-7.883065,"marketCap":509089757},{"date":"2024-10-04","current":-12.12104,"twenty":-12.018852,"median":-10.468381,"eighty":-7.937424,"marketCap":577046353},{"date":"2024-10-11","current":-13.141817,"twenty":-12.215183,"median":-10.579508,"eighty":-7.980207,"marketCap":625642465},{"date":"2024-10-18","current":-14.443716,"twenty":-12.644595,"median":-10.678753,"eighty":-7.993293,"marketCap":687621999},{"date":"2024-10-25","current":-13.155463,"twenty":-12.975228,"median":-10.69616,"eighty":-8.014936,"marketCap":626292146},{"date":"2024-10-31","current":-11.938174,"twenty":-12.976568,"median":-10.764003,"eighty":-8.053188,"marketCap":568340632},{"date":"2024-11-08","current":-18.968977,"twenty":-13.201862,"median":-10.833215,"eighty":-8.053188,"marketCap":903056103},{"date":"2024-11-15","current":-10.699049,"twenty":-13.232134,"median":-10.867118,"eighty":-8.053188,"marketCap":509349629},{"date":"2024-11-22","current":-3.804354,"twenty":-13.201862,"median":-10.811892,"eighty":-8.005373,"marketCap":202570426},{"date":"2024-11-29","current":-7.081932,"twenty":-13.164743,"median":-10.73726,"eighty":-7.916284,"marketCap":377091628},{"date":"2024-12-06","current":-6.123936,"twenty":-13.144546,"median":-10.69616,"eighty":-7.738107,"marketCap":326081199},{"date":"2024-12-13","current":-6.220014,"twenty":-13.009618,"median":-10.678753,"eighty":-7.632912,"marketCap":331197071},{"date":"2024-12-20","current":-6.147607,"twenty":-12.971208,"median":-10.579508,"eighty":-7.59013,"marketCap":327341631},{"date":"2024-12-27","current":-6.711544,"twenty":-12.908645,"median":-10.50763,"eighty":-7.57654,"marketCap":357369573},{"date":"2025-01-03","current":-6.374574,"twenty":-12.853892,"median":-10.405691,"eighty":-7.549864,"marketCap":339426951},{"date":"2025-01-10","current":-5.995231,"twenty":-12.800672,"median":-10.212067,"eighty":-7.505069,"marketCap":319228040},{"date":"2025-01-17","current":-4.918377,"twenty":-12.651961,"median":-10.173232,"eighty":-7.427764,"marketCap":261888801},{"date":"2025-01-24","current":-4.346472,"twenty":-12.574112,"median":-10.030358,"eighty":-7.086806,"marketCap":231436615},{"date":"2025-01-31","current":-4.332524,"twenty":-12.537284,"median":-9.920586,"eighty":-6.842433,"marketCap":230693879},{"date":"2025-02-07","current":-6.50018,"twenty":-12.535901,"median":-9.842528,"eighty":-6.605719,"marketCap":346115092},{"date":"2025-02-14","current":-5.236411,"twenty":-12.52887,"median":-9.777894,"eighty":-6.491539,"marketCap":278823188},{"date":"2025-02-21","current":-4.829104,"twenty":-12.471907,"median":-9.750601,"eighty":-6.430271,"marketCap":257135289},{"date":"2025-02-28","current":-4.770518,"twenty":-12.349943,"median":-9.721942,"eighty":-6.303838,"marketCap":254015797},{"date":"2025-03-07","current":-4.672876,"twenty":-12.236804,"median":-9.661093,"eighty":-6.2189,"marketCap":248816643},{"date":"2025-03-14","current":-4.686825,"twenty":-12.214976,"median":-9.588204,"eighty":-6.130619,"marketCap":249559380},{"date":"2025-03-21","current":-4.24883,"twenty":-12.149292,"median":-9.555425,"eighty":-6.004158,"marketCap":226237461},{"date":"2025-03-28","current":-3.045755,"twenty":-12.12341,"median":-9.468113,"eighty":-5.45457,"marketCap":228870246},{"date":"2025-04-04","current":-1.92123,"twenty":-12.043093,"median":-9.418302,"eighty":-5.225252,"marketCap":144368903},{"date":"2025-04-11","current":-1.782154,"twenty":-12.004592,"median":-9.374415,"eighty":-5.034123,"marketCap":133918207},{"date":"2025-04-17","current":-2.044108,"twenty":-11.997937,"median":-9.328916,"eighty":-4.961897,"marketCap":153602450},{"date":"2025-04-25","current":-2.917172,"twenty":-11.976697,"median":-9.167755,"eighty":-4.922368,"marketCap":219207954},{"date":"2025-05-02","current":-2.922866,"twenty":-11.956745,"median":-9.074937,"eighty":-4.83359,"marketCap":219635816},{"date":"2025-05-09","current":-2.846947,"twenty":-11.943832,"median":-8.430682,"eighty":-4.764939,"marketCap":213930990},{"date":"2025-05-16","current":-3.416053,"twenty":-11.921952,"median":-8.053188,"eighty":-4.703006,"marketCap":276256218},{"date":"2025-05-23","current":-3.181497,"twenty":-11.907794,"median":-8.053188,"eighty":-4.667296,"marketCap":257287670},{"date":"2025-05-30","current":-3.304948,"twenty":-11.891321,"median":-7.997823,"eighty":-4.63103,"marketCap":267271116},{"date":"2025-06-06","current":-4.042124,"twenty":-11.854896,"median":-7.927357,"eighty":-4.432955,"marketCap":326886552},{"date":"2025-06-13","current":-3.597702,"twenty":-11.83216,"median":-7.80656,"eighty":-4.329176,"marketCap":290946146},{"date":"2025-06-20","current":-3.22735,"twenty":-11.824338,"median":-7.733577,"eighty":-4.305184,"marketCap":260995807},{"date":"2025-06-27","current":-2.922251,"twenty":-11.790759,"median":-7.659337,"eighty":-4.202034,"marketCap":236322433},{"date":"2025-07-03","current":-3.543031,"twenty":-11.778088,"median":-7.622846,"eighty":-3.964273,"marketCap":286524905},{"date":"2025-07-11","current":-3.87282,"twenty":-11.778088,"median":-7.593905,"eighty":-3.821676,"marketCap":313194969},{"date":"2025-07-18","current":-3.985689,"twenty":-11.771752,"median":-7.587614,"eighty":-3.805804,"marketCap":322322691},{"date":"2025-07-25","current":-4.022724,"twenty":-11.764996,"median":-7.573772,"eighty":-3.819913,"marketCap":325317725},{"date":"2025-08-01","current":-3.839312,"twenty":-11.670697,"median":-7.549864,"eighty":-3.819913,"marketCap":310485176},{"date":"2025-08-08","current":-3.784641,"twenty":-11.657709,"median":-7.513374,"eighty":-3.804354,"marketCap":306063936},{"date":"2025-08-15","current":-3.416033,"twenty":-11.655175,"median":-7.497015,"eighty":-3.77935,"marketCap":288292703},{"date":"2025-08-22","current":-3.339933,"twenty":-11.654541,"median":-7.373701,"eighty":-3.740907,"marketCap":281870341},{"date":"2025-08-29","current":-3.186043,"twenty":-11.623292,"median":-7.086806,"eighty":-3.597702,"marketCap":268882897},{"date":"2025-09-05","current":-3.316258,"twenty":-11.587469,"median":-7.081932,"eighty":-3.564545,"marketCap":279872272},{"date":"2025-09-12","current":-3.39574,"twenty":-11.537964,"median":-6.776988,"eighty":-3.481558,"marketCap":286580073},{"date":"2025-09-19","current":-3.158985,"twenty":-11.502485,"median":-6.605719,"eighty":-3.434395,"marketCap":266599390},{"date":"2025-09-26","current":-2.943369,"twenty":-11.461109,"median":-6.573692,"eighty":-3.385336,"marketCap":248402697},{"date":"2025-10-03","current":-3.547939,"twenty":-11.450166,"median":-6.491539,"eighty":-3.377814,"marketCap":299424797},{"date":"2025-10-10","current":-5.337129,"twenty":-11.445253,"median":-6.449765,"eighty":-3.380182,"marketCap":450421668},{"date":"2025-10-17","current":-5.748068,"twenty":-11.407188,"median":-6.374574,"eighty":-3.383551,"marketCap":485102424},{"date":"2025-10-24","current":-4.855164,"twenty":-11.397945,"median":-6.302167,"eighty":-3.385336,"marketCap":409746708},{"date":"2025-10-31","current":-5.604324,"twenty":-11.395615,"median":-6.221406,"eighty":-3.393711,"marketCap":472971296},{"date":"2025-11-07","current":-4.508487,"twenty":-11.353547,"median":-6.20957,"eighty":-3.411974,"marketCap":380489280},{"date":"2025-11-14","current":-4.862014,"twenty":-11.286405,"median":-6.13229,"eighty":-3.416049,"marketCap":410324802},{"date":"2025-11-21","current":-3.711875,"twenty":-11.19565,"median":-6.083345,"eighty":-3.434395,"marketCap":315991920},{"date":"2025-11-28","current":-3.835604,"twenty":-11.143862,"median":-6.000811,"eighty":-3.441096,"marketCap":326524984},{"date":"2025-12-05","current":-3.850161,"twenty":-11.110635,"median":-5.793728,"eighty":-3.451989,"marketCap":327764168},{"date":"2025-12-12","current":-3.868356,"twenty":-11.06004,"median":-5.680588,"eighty":-3.464399,"marketCap":329313148},{"date":"2025-12-19","current":-3.508086,"twenty":-11.030846,"median":-5.604324,"eighty":-3.47695,"marketCap":298643344},{"date":"2025-12-26","current":-3.65183,"twenty":-11.024546,"median":-5.462383,"eighty":-3.4835,"marketCap":310880286},{"date":"2026-01-02","current":-3.748266,"twenty":-11.014016,"median":-5.423319,"eighty":-3.488028,"marketCap":319089880},{"date":"2026-01-09","current":-3.398913,"twenty":-11.004191,"median":-5.362496,"eighty":-3.47056,"marketCap":289349464},{"date":"2026-01-16","current":-3.286101,"twenty":-10.982901,"median":-5.337129,"eighty":-3.424394,"marketCap":279745788},{"date":"2026-01-23","current":-3.455319,"twenty":-10.950149,"median":-5.255956,"eighty":-3.416033,"marketCap":294151302},{"date":"2026-01-30","current":-3.437123,"twenty":-10.917397,"median":-5.24669,"eighty":-3.416033,"marketCap":292602322},{"date":"2026-02-06","current":-2.978598,"twenty":-10.901021,"median":-5.220443,"eighty":-3.384309,"marketCap":253568026},{"date":"2026-02-13","current":-3.093229,"twenty":-10.833215,"median":-5.176431,"eighty":-3.360227,"marketCap":263326600},{"date":"2026-02-20","current":-3.387996,"twenty":-10.826322,"median":-5.1238,"eighty":-3.344395,"marketCap":288420076},{"date":"2026-02-27","current":-3.580868,"twenty":-10.814433,"median":-5.042522,"eighty":-3.344395,"marketCap":304839264},{"date":"2026-03-06","current":-4.026657,"twenty":-10.794975,"median":-4.976962,"eighty":-3.351841,"marketCap":342789274},{"date":"2026-03-13","current":-4.057589,"twenty":-10.747957,"median":-4.935115,"eighty":-3.358866,"marketCap":345422540},{"date":"2026-03-20","current":-3.49171,"twenty":-10.706691,"median":-4.921703,"eighty":-3.363519,"marketCap":297249262},{"date":"2026-03-27","current":-3.690558,"twenty":-10.698793,"median":-4.862014,"eighty":-3.371873,"marketCap":333445613},{"date":"2026-04-02","current":-3.733652,"twenty":-10.695646,"median":-4.843053,"eighty":-3.36999,"marketCap":337339186},{"date":"2026-04-10","current":-3.683663,"twenty":-10.688456,"median":-4.832842,"eighty":-3.3768,"marketCap":332822641},{"date":"2026-04-17","current":-4.417982,"twenty":-10.681265,"median":-4.798416,"eighty":-3.3768,"marketCap":399169129},{"date":"2026-04-24","current":-4.657895,"twenty":-10.639691,"median":-4.783762,"eighty":-3.379844,"marketCap":420845432},{"date":"2026-05-01","current":-4.509257,"twenty":-10.598077,"median":-4.75657,"eighty":-3.382793,"marketCap":407415856},{"date":"2026-05-08","current":-5.402812,"twenty":-10.577871,"median":-4.776107,"eighty":-3.385079,"marketCap":488149470},{"date":"2026-05-15","current":-5.009484,"twenty":-10.556655,"median":-4.798416,"eighty":-3.387035,"marketCap":494125444},{"date":"2026-05-22","current":-4.423148,"twenty":-10.49978,"median":-4.779444,"eighty":-3.392642,"marketCap":436290486},{"date":"2026-05-29","current":-4.405526,"twenty":-10.464613,"median":-4.763544,"eighty":-3.397009,"marketCap":434552277},{"date":"2026-06-05","current":-4.402322,"twenty":-10.416345,"median":-4.734251,"eighty":-3.405761,"marketCap":434236239},{"date":"2026-06-12","current":-4.645827,"twenty":-10.296743,"median":-4.709778,"eighty":-3.416041,"marketCap":458255129},{"date":"2026-06-18","current":-4.932587,"twenty":-10.212762,"median":-4.709778,"eighty":-3.416992,"marketCap":486540531},{"date":"2026-06-26","current":-4.871711,"twenty":-10.209654,"median":-4.734251,"eighty":-3.424023,"marketCap":480535809},{"date":"2026-07-02","current":-5.427608,"twenty":-10.20463,"median":-4.75657,"eighty":-3.437123,"marketCap":535368405},{"date":"2026-07-10","current":-8.654559,"twenty":-10.173232,"median":-4.779444,"eighty":-3.438943,"marketCap":853668396},{"date":"2026-07-17","current":-7.373749,"twenty":-10.082175,"median":-4.785829,"eighty":-3.43898,"marketCap":727331850},{"date":"2026-07-24","current":-7.18587,"twenty":-10.030358,"median":-4.808949,"eighty":-3.442507,"marketCap":708799833},{"date":"2026-07-31","current":-6.787889,"twenty":-9.971335,"median":-4.824919,"eighty":-3.452757,"marketCap":669543840},{"date":"2026-08-07","current":-7.19193,"twenty":-9.939181,"median":-4.840263,"eighty":-3.457713,"marketCap":709397640},{"date":"2026-08-14","current":-6.417114,"twenty":-9.912039,"median":-4.858589,"eighty":-3.464651,"marketCap":713005540},{"date":"2026-08-21","current":-6.84216,"twenty":-9.89127,"median":-4.877395,"eighty":-3.468013,"marketCap":760232402},{"date":"2026-08-28","current":-6.818746,"twenty":-9.851523,"median":-4.921703,"eighty":-3.473763,"marketCap":757630922},{"date":"2026-09-04","current":-6.77372,"twenty":-9.81593,"median":-4.932587,"eighty":-3.478196,"marketCap":752628077},{"date":"2026-09-11","current":-6.505365,"twenty":-9.792905,"median":-4.943801,"eighty":-3.478973,"marketCap":722811117},{"date":"2026-09-18","current":-5.837178,"twenty":-9.777075,"median":-4.976962,"eighty":-3.481156,"marketCap":648568890},{"date":"2026-09-25","current":-5.628257,"twenty":-9.763974,"median":-5.001836,"eighty":-3.483945,"marketCap":625355687},{"date":"2026-10-02","current":-4.781768,"twenty":-9.749236,"median":-5.009992,"eighty":-3.488959,"marketCap":531302192},{"date":"2026-10-08","current":-4.659297,"twenty":-9.739983,"median":-5.001181,"eighty":-3.495349,"marketCap":517694452}],"updateTime":1791565938354},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NGNE\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2635222850","title":"Neurogene posts corporate deck highlighting NGN-401 gene therapy program for Rett syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2635222850","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635222850?lang=en_us&edition=fundamental","pubTime":"2026-05-13 04:41","pubTimestamp":1778618494,"startTime":"0","endTime":"0","summary":"Neurogene highlighted NGN-401 as a one-time gene therapy candidate for Rett syndrome, supported by interim Phase 1/2 data showing functional improvements across core domains in 100% of participants, with 35 total developmental milestones gained and no plateau reported out to 24 months.Safety profile at 1E15 vg dose described as generally well tolerated in 10 participants, with treatment-emergent adverse events related to NGN-401 limited to Grade 1 or Grade 2; most participants had mild liver enzyme elevations.Registration plan centers on Embolden, a single-arm, baseline-controlled, open-label trial in females aged ≥3 years  using a responder-based composite endpoint at 12 months; success threshold set at 35%, or 7 of 20 participants.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpret","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nNDL3sVGsT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NGNE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635247714","title":"Neurogene Q1 net loss widens on higher R&D costs","url":"https://stock-news.laohu8.com/highlight/detail?id=2635247714","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635247714?lang=en_us&edition=fundamental","pubTime":"2026-05-13 04:13","pubTimestamp":1778616821,"startTime":"0","endTime":"0","summary":"Neurogene Q1 net loss widens on higher R&D costsOverviewU.S. gene therapy developer's Q1 net loss widened due to higher R&D expensesCompany has dosed ~90% of participants in Embolden trial for Rett sy","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nL1N41P1D6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NGNE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635471682","title":"Neurogene Q1 FY26 net loss widens to USD 30.9 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2635471682","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635471682?lang=en_us&edition=fundamental","pubTime":"2026-05-13 04:08","pubTimestamp":1778616537,"startTime":"0","endTime":"0","summary":"Neurogene posted a Q1 net loss of USD 30.9 million, widening from USD 22.6 million a year earlier, with loss per share deepening to USD 1.39 from USD 1.08.R&D expense rose to USD 25.2 million from USD 17.8 million, while G&A expense was little changed at USD 8.2 million.Cash, cash equivalents, short-term investments totaled USD 243.2 million as of March 31, expected to fund operations through Q1 2028.About 90% of participants have been dosed in Embolden registrational trial for Rett syndrome gene therapy NGN-401, with dosing on track to finish in Q2 2026.NGN-401 at 1E15 vg has been generally well-tolerated, with no HLH cases reported in Phase 1/2 or Embolden as of May 11.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurogene Inc. pu","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nNDL9GSTWr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NGNE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635475972","title":"BRIEF-Neurogene Q1 Operating Expenses USD 33.349 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2635475972","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635475972?lang=en_us&edition=fundamental","pubTime":"2026-05-13 04:05","pubTimestamp":1778616346,"startTime":"0","endTime":"0","summary":"BRIEF-Neurogene Q1 Operating Expenses USD 33.349 Million\n\n\nMay 12 (Reuters) - Neurogene Q1 operating income USD -33.349 million.\n\nQ1 net income USD -30.934 million","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nPLXB88F00:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NGNE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635247600","title":"Press Release: Neurogene Reports First Quarter 2026 Financial Results and Highlights Recent Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2635247600","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635247600?lang=en_us&edition=fundamental","pubTime":"2026-05-13 04:05","pubTimestamp":1778616300,"startTime":"0","endTime":"0","summary":"Dosed 90% of participants in Embolden registrational trial of NGN-401 for Rett syndrome; on track to complete dosing in the second quarter of 2026. NGN-401 has been generally well-tolerated, with no cases of HLH at the 1E15 vg dose; additional interim Phase 1/2 data expected mid-2026. Presentation at ASGCT Meeting highlighted therapeutic rationale for ICV delivery in CNS-targeted gene therapy, including NGN-401. Strong cash position provides runway through first quarter of 2028. Neurogene Inc. , a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced first quarter 2026 financial results and highlighted recent corporate updates.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2237443895.HKD","LU2237443465.HKD","CMC","BK4555","BK4006","LU0170899867.USD","LU2746668461.USD","BK4139","IE00BFXG1179.USD","LU0882574139.USD","LU1363072403.SGD","LU0149725797.USD","IE00BZ1G4Q59.USD","LU2237443622.USD","BK4585","03160","IE00BHPRN162.USD","TM","IE00B1BXHZ80.USD","BK4099","LU2237443549.SGD","LU2237443978.SGD","NGNE","LU2237443382.USD","LU2746668974.SGD","IE00BKVL7J92.USD","BK4604","LU0267386448.USD","BK4588","CNS","BK4135","LU0971096721.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634292787","title":"Neurogene says NGN-401 Rett trial shows milestone gains up to 24 months","url":"https://stock-news.laohu8.com/highlight/detail?id=2634292787","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634292787?lang=en_us&edition=fundamental","pubTime":"2026-05-12 18:00","pubTimestamp":1778580052,"startTime":"0","endTime":"0","summary":"Preclinical findings indicated broader distribution in brain regions tied to Rett syndrome versus an alternative spinal-fluid delivery approach, supporting strategy for its NGN-401 program.Phase 1/2 Rett syndrome readout described functional gains that continued over time, with treatment generally well tolerated through an October 30, 2025 data cutoff.Company is using same delivery method in Embolden registrational trial, positioning it as a scalable clinical approach that could support outpatient-style monitoring.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nNDLcgc59L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NGNE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633468287","title":"Neurogene President, CFO Christine Mikail Cvijic sells USD 300,821 common shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2633468287","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633468287?lang=en_us&edition=fundamental","pubTime":"2026-05-08 23:51","pubTimestamp":1778255518,"startTime":"0","endTime":"0","summary":"Neurogene President, CFO, director Christine Mikail Cvijic reported sale of 9,600 common shares on May 6.Sales priced at USD 30.07 per share for 4,800 shares, USD 32.44 per share for 4,800 shares.Directly held stake fell to 93,640 shares following transactions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurogene Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 08, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nNDL9tb0GC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Neurogene President, CFO Christine Mikail Cvijic sells USD 300,821 common shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NGNE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633150773","title":"BRIEF-Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2633150773","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633150773?lang=en_us&edition=fundamental","pubTime":"2026-05-07 05:11","pubTimestamp":1778101863,"startTime":"0","endTime":"0","summary":"BRIEF-Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)Neurogene Inc NGNE.O:NEUROGENE ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)Source text: ID:nBw7d2wKgaFurther company coverage: NGNE.O","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260506:nTUA2L1FCB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NGNE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633977159","title":"Neurogene grants 122,565 inducement stock options to two new employees","url":"https://stock-news.laohu8.com/highlight/detail?id=2633977159","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633977159?lang=en_us&edition=fundamental","pubTime":"2026-05-07 04:03","pubTimestamp":1778097793,"startTime":"0","endTime":"0","summary":"Neurogene granted non-qualified stock options for 122,565 shares to two new employees on May 5, 2026.Options covering 120,000 shares went to Chief Commercial Officer Christy Shafer, with vesting commencing April 20, 2026.Exercise price set at closing price of common stock on grant date.Vesting runs four years, with 25% vesting on first anniversary of vesting commencement date, then 1/48 vesting monthly over next three years, subject to continued employment.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurogene Inc. published the original content used to generate this news brief via Business Wire  on May 06, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260506:nNDL6t5V58:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NGNE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633949611","title":"Neurogene Inc  expected to post a loss of $1.30 a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2633949611","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633949611?lang=en_us&edition=fundamental","pubTime":"2026-05-05 22:25","pubTimestamp":1777991121,"startTime":"0","endTime":"0","summary":"Neurogene Inc  expected to post a loss of $1.30 a share - Earnings Preview Neurogene Inc NGNE.OQ NGNE.O is expected to  show no change in quarterly revenue when it reports  results on May 7 (estimated","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260505:nL8N41I25X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NGNE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630330950","title":"Guggenheim Initiates Neurogene at Buy With $69 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2630330950","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630330950?lang=en_us&edition=fundamental","pubTime":"2026-04-28 19:38","pubTimestamp":1777376296,"startTime":"0","endTime":"0","summary":"Neurogene (NGNE) has an average rating of buy and mean price target of $76.43, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks and","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NGNE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630306232","title":"Neurogene highlights NGN-401 Phase 1/2 Rett syndrome data ahead of ASGCT poster","url":"https://stock-news.laohu8.com/highlight/detail?id=2630306232","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630306232?lang=en_us&edition=fundamental","pubTime":"2026-04-28 19:36","pubTimestamp":1777376181,"startTime":"0","endTime":"0","summary":"Presentation will highlight preclinical findings supporting broader brain and nervous system distribution for NGN-401 in Rett syndrome versus intrathecal-lumbar delivery.Poster will also review clinical observations indicating tolerability for ICV administration, with safety driven primarily by product profile rather than delivery route.Neurogene pointed to ongoing Phase 1/2 NGN-401 trial showing durable, multidomain developmental milestone gains over time, supporting continued advancement into Embolden registrational study.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260428:nNDL9xTWlq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NGNE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628405557","title":"BRIEF-Neurogene Appoints Christy Shafer As Chief Commercial Officer And Christine Mikail, J.D., To Board Of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2628405557","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628405557?lang=en_us&edition=fundamental","pubTime":"2026-04-20 19:57","pubTimestamp":1776686247,"startTime":"0","endTime":"0","summary":"BRIEF-Neurogene Appoints Christy Shafer As Chief Commercial Officer And Christine Mikail, J.D., To Board Of DirectorsNeurogene Inc NGNE.O:NEUROGENE APPOINTS CHRISTY SHAFER AS CHIEF COMMERCIAL OFFICER ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260420:nTUA9M3FZM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NGNE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628747633","title":"Neurogene names Christy Shafer chief commercial officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2628747633","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628747633?lang=en_us&edition=fundamental","pubTime":"2026-04-20 19:30","pubTimestamp":1776684619,"startTime":"0","endTime":"0","summary":"Neurogene named Christy Shafer chief commercial officer to lead commercial strategy and launch readiness for NGN-401 gene therapy in Rett syndrome.Shafer previously served as senior vice president and general manager, North America, at Avidity Biosciences.She was formerly chief commercial officer at Marinus Pharmaceuticals, leading launch of Ztalmy for seizures linked to CDKL5 deficiency disorder.Neurogene added Christine Mikail, president and CFO, to board of directors.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260420:nNDL94v9M2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NGNE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628747521","title":"Neurogene Appoints Christy Shafer as Chief Commercial Officer and Christine Mikail, J.d., to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2628747521","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628747521?lang=en_us&edition=fundamental","pubTime":"2026-04-20 19:30","pubTimestamp":1776684600,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260420:nTUA9M3FZM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NGNE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628744168","title":"Companies Like Neurogene (NASDAQ:NGNE) Are In A Position To Invest In Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2628744168","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628744168?lang=en_us&edition=fundamental","pubTime":"2026-04-20 18:16","pubTimestamp":1776680194,"startTime":"0","endTime":"0","summary":"Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ngne/neurogene/news/companies-like-neurogene-nasdaqngne-are-in-a-position-to-inv","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ngne/neurogene/news/companies-like-neurogene-nasdaqngne-are-in-a-position-to-inv","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["JEPQ","BK4139","QQQM","TQQQ","NGNE","MNQmain",".IXIC","PSQ","QYLG","SQQQ","QQQE","QQQJ","TQQY","NDX","GPIQ","QLD","QID","IYW","QQQA","QDTE","NVIW.SI","ONEQ","NQmain","QQQ","FTEC","QQQY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628315249","title":"Neurogene announces annual shareholder meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2628315249","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628315249?lang=en_us&edition=fundamental","pubTime":"2026-04-17 04:16","pubTimestamp":1776370618,"startTime":"0","endTime":"0","summary":"Neurogene scheduled 2026 annual stockholder meeting for June 3, 2026 in virtual format.Ballot includes election of Robert Baffi, Ph.D. plus Rohan Palekar as Class III directors with terms running to 2029.Stockholders will cast advisory vote on named executive officer compensation.Meeting will also include advisory vote on frequency of future executive pay votes, with choices of one, two, or three years.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurogene Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 16, 2026, and is solely responsible for the information contained therei","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260416:nNDLb7PLrG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NGNE"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":4,"totalSize":77,"code":"91000000","status":"200"}]}}